Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US federal district court in Boston has ruled that Roche's pegylated-erythropoietin product Mircera infringes 11 Amgen erythropoietin patent claims.
Subscribe to our email newsletter
Amgen said that it will seek an injunction to prevent Roche from commercializing Mircera, which is used in the treatment of anemia, in the US in violation of Amgen’s affirmed patent rights. The injunction hearing is scheduled for November 15, 2007.
California-based Amgen said that it “firmly believes Roche’s peg-EPO product provides no clinical or patient benefit over Amgen’s innovative therapies, Epogen and Aranesp.”